乳腺癌特异基因1在三阴性乳腺癌中的表达与免疫治疗疗效及预后分析  

Analysis of the status of breast cancer specific gene 1 in triple negative breast cancer cancer patients and the efficacy and prognosis of immunotherapy

作　　者：邱文秀 王苗锋 QIU Wenxiu;WANG Miaofeng(Department of Breast Surgery,Shaoxing Keqiao Women&Children's Hospital,Shaoxing,Zhejiang 312030,China;Department of Breast Surgery,Shaoxing Central Hospital,Shaoxing,Zhejiang 312030,China)

机构地区：[1]绍兴市柯桥区妇幼保健院乳腺外科,浙江绍兴312030 [2]绍兴市中心医院甲乳外科,浙江绍兴312030

出　　处：《中国优生与遗传杂志》2024年第1期86-91,共6页Chinese Journal of Birth Health & Heredity

摘　　要：目的探究乳腺癌特异基因1(BCSG1)在三阴性乳腺癌(TNBC)患者中的状态与免疫治疗疗效及预后的关系。方法选择2016年9月至2022年1月于绍兴市柯桥区妇幼保健院乳腺外科和绍兴市中心医院甲乳外科接受免疫治疗的TNBC患者150例为研究对象,根据患者BCSG1蛋白的表达水平,分为高表达组(n=78)和低表达组(n=72),分析BCSG1表达水平和免疫治疗疗效的关系;依据患者预后分为预后不良组(n=53)和预后良好组(n=97),探究患者治疗后预后不良的危险因素,并构建预测模型。采用Kaplan-Meier生存曲线对不同BCSG1表达水平患者的生存率进行相关分析。结果BCSG1表达水平与肿瘤直径、TNM分期、肿瘤分化程度及淋巴结转移之间存在密切联系(P<0.05)。BCSG1低表达组治疗有效率为79.17%,BCSG1高表达组治疗有效率为53.85%,BCSG1高表达与免疫治疗疗效呈负相关(P<0.05)。预后不良组患者相比于预后良好组年龄较大、肿瘤直径较大、BCSG1表达水平较高、绝经、脉管癌栓、淋巴结转移、远处转移发生较多、TNM分期主要为Ⅲ~Ⅳ期、肿瘤分化程度主要为低分化(P<0.05)。肿瘤大小≥5 cm、TNM分期Ⅲ~Ⅳ、肿瘤低分化、淋巴结转移、BCSG1高表达是TNBC患者免疫治疗后预后不良的独立危险因素(P<0.05)。Kaplan-Meier生存曲线显示BCSG1高表达的患者生存率较BCSG1低表达的患者低(P<0.05)。结论肿瘤直径较大、TNM分期Ⅲ~Ⅳ、肿瘤分化程度较低以及淋巴结转移的TNBC患者的BCSG1表达水平较高,BCSG1高表达是TNBC患者免疫治疗后预后不良的独立危险因素,可作为免疫治疗疗效及预后的有效预测因子。Objective To investigate the relationship between the status of BCSG1 and the efficacy and prognosis of immunotherapy in triple negative breast cancer(TNBC).Methods 150 patients with TNBC who received immunotherapy in the two hospitals from September 2016 to January 2022 were selected as research objects to detect the expression of BCSG1in cancer tissues.According to the expression level of BCSG1,the patients were divided into high expression group(n=78)and low expression group(n=72)to explore the relationship between the expression level of BCSG1 and pathological features and the efficacy of immunotherapy.According to the prognosis,patients were divided into poor prognosis group(n=53)and good prognosis group(n=97),to explore the risk factors of poor prognosis after treatment,and build a prediction model.The survival rate of patients with different levels of BCSG1 expression was analyzed by using Kaplan-Meier survival curve.Results The expression level of BCSG1 was closely related to tumor diameter,TNM stage,tumor differentiation and lymph node metastasis(P<0.05).The effective rate of BCSG1 low expression group was 79.17%,and that of BCSG1 high expression group was 53.85%.The high expression of BCSG1 was negatively correlated with the efficacy of immunotherapy(P<0.05).Compared with the patients with good prognosis,the patients with poor prognosis were older,the tumor diameter was larger,the expression level of BCSG1 was higher,menopause,vascular tumor thrombus,lymph node metastasis,distant metastasis occurred more,TNM stage was mainly stage III-IV,and the degree of tumor differentiation was mainly poor(P<0.05).Tumor size≥5 cm,TNM stage Ⅲ-Ⅳ,low differentiation of tumor,lymph node metastasis,and high expression of BCSG1 were independent risk factors for poor prognosis of patients with TNBC after immunotherapy(P<0.05).Kaplan-Meier survival curve showed that the survival rate of patients with high expression of BCSG1 was lower than that of patients with low expression of BCSG1(P<0.05).Conclusion The expression

关 键 词：三阴性乳腺癌 特异基因1 免疫治疗 疗效 预后 

分 类 号：R737.9[医药卫生—肿瘤]